These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38814401)

  • 1. Producing Plasmid DNA Template for Clinical Grade RNA Vaccine Manufacture.
    Shankar R; Schmeer M; Schleef M
    Methods Mol Biol; 2024; 2786():303-319. PubMed ID: 38814401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upstream processing of plasmid DNA for vaccine and gene therapy applications.
    Tejeda-Mansir A; Montesinos RM
    Recent Pat Biotechnol; 2008; 2(3):156-72. PubMed ID: 19075863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmid fermentation process for DNA immunization applications.
    Carnes AE; Williams JA
    Methods Mol Biol; 2014; 1143():197-217. PubMed ID: 24715290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccine manufacture: scale and quality.
    Cai Y; Rodriguez S; Hebel H
    Expert Rev Vaccines; 2009 Sep; 8(9):1277-91. PubMed ID: 19722898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of new plasmid DNA vaccine vectors with R1-based replicons.
    Bower DM; Prather KL
    Microb Cell Fact; 2012 Aug; 11():107. PubMed ID: 22889338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies.
    Przybylowski M; Bartido S; Borquez-Ojeda O; Sadelain M; Rivière I
    Vaccine; 2007 Jun; 25(27):5013-24. PubMed ID: 17537555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA: the new revolution in nucleic acid vaccines.
    Geall AJ; Mandl CW; Ulmer JB
    Semin Immunol; 2013 Apr; 25(2):152-9. PubMed ID: 23735226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production and purification of plasmid DNA vaccines: is there scope for further innovation?
    Xenopoulos A; Pattnaik P
    Expert Rev Vaccines; 2014 Dec; 13(12):1537-51. PubMed ID: 25308708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human clinical trials of plasmid DNA vaccines.
    Liu MA; Ulmer JB
    Adv Genet; 2005; 55():25-40. PubMed ID: 16291211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA-based vaccines.
    Ulmer JB; Mason PW; Geall A; Mandl CW
    Vaccine; 2012 Jun; 30(30):4414-8. PubMed ID: 22546329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Considerations on the Development of mRNA Vaccines.
    Naik R; Peden K
    Curr Top Microbiol Immunol; 2022; 440():187-205. PubMed ID: 32638114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-dose plasmid-launched live-attenuated Zika vaccine induces protective immunity.
    Zou J; Xie X; Luo H; Shan C; Muruato AE; Weaver SC; Wang T; Shi PY
    EBioMedicine; 2018 Oct; 36():92-102. PubMed ID: 30201444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in host and vector development for the production of plasmid DNA vaccines.
    Mairhofer J; Lara AR
    Methods Mol Biol; 2014; 1139():505-41. PubMed ID: 24619702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process.
    Nelson J; Rodriguez S; Finlayson N; Williams J; Carnes A
    Hum Vaccin Immunother; 2013 Oct; 9(10):2211-5. PubMed ID: 23899469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a Plasmid DNA-Based Alphavirus Vaccine on Immunization Efficiency.
    Lundstrom K
    Methods Mol Biol; 2021; 2197():33-47. PubMed ID: 32827131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel synthetic plasmid and Doggybone DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice.
    Scott VL; Patel A; Villarreal DO; Hensley SE; Ragwan E; Yan J; Sardesai NY; Rothwell PJ; Extance JP; Caproni LJ; Weiner DB
    Hum Vaccin Immunother; 2015; 11(8):1972-82. PubMed ID: 26091432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent innovations in mRNA vaccines.
    Ulmer JB; Geall AJ
    Curr Opin Immunol; 2016 Aug; 41():18-22. PubMed ID: 27240054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.